Higher TMB, PD-L1 Expression Correlate With Shorter Survival in Hematologic Malignancies
Miles Matter: The Geographic Disparity That Impacts Access to CAR T Therapy
Preclinical Model Suggests Efficacy of Combining Capivasertib With Venetoclax Against DLBCL
Combination of Magrolimab and Rituximab Well Tolerated in Patients With Refractory/Relapsed Indolent NHL
Dr Anna Sureda on the Evolving Treatment Landscape for Relapsed/Refractory DLBCL, Follicular Lymphoma
Dr Ann LaCasce: T-Cell Engagers Have Improved DLBCL Outcomes, but Questions on Optimal Use Remain
Epcoritamab Approval Expands Treatment Armamentarium for DLBCL
ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care
Recent Advances in BCMA-Directed Treatment in Multiple Myeloma: Insights and Application for Managed Care
Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy
Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care
Closing Gaps in CLL Care: Managed Care Insights and Strategies
Advancements in R/R Lymphoma: Bispecific Antibodies in Focus